Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Diabetes Metab Syndr. 2022 Oct;16(10):102620. doi: 10.1016/j.dsx.2022.102620. Epub 2022 Sep 15.
Examine the glycemic control on Type 1 Diabetes (T1D) wearing the Flash Glucose Monitoring (FGM) system for a one-year period of time.
This prospective study done using 187 patients with T1D (14-40yrs) who self-tested their glucose levels by FGM. Continuous glucose monitoring (CGM) metrics were gathered i.e., Glucose Variability (GV) (%), mean Time in Range (TIR), Time Above Range (TAR), Time Below Range (TBR), and average duration of hypoglycemic events at the 3, 6, and 12 month time periods.
At 6th, 9th and 12th months, for values of GV, % in target, TAR and %>250 mg/dL, no significant changes (p > 0.05) were noted compared to 3 months. However, significant changes from the baseline were evident for the values of the mean glucose level at the 3rd (p = 0.028), 9th (p = 0.048) and 12th months (p = 0.022). When the mean glucose value at 3 months was compared to the same at 6, 9, and 12 month period, no significant changes (p > 0.05) were seen. When compared with baseline values, low glucose events at 3 months (p = 0.028), 6 months (p = 0.048), 9 months (p = 0.022) and 12 months (p = 0.038) showed significant changes. However, the percentage below 70 mg/dL (barring the value at 12 months, p = 0.046), no significant changes were observed. The HbA1c revealed significant drop in 3, 6, 9 and 12 months compared to baseline values.
Significant improvement was noted in CGM metrics when patients switched from conventional finger pricking method over to FGM system, and the effect was observed during the entire study period.
研究使用瞬态血糖监测系统(Flash Glucose Monitoring,FGM)对 1 型糖尿病(Type 1 Diabetes,T1D)患者进行为期 1 年的血糖控制情况。
本前瞻性研究纳入 187 名 T1D 患者(年龄 14-40 岁),这些患者通过 FGM 进行自我血糖检测。连续血糖监测(Continuous glucose monitoring,CGM)指标包括血糖变异性(Glucose Variability,GV)(%)、平均血糖达标时间(Time in Range,TIR)、血糖高于目标范围时间(Time Above Range,TAR)、血糖低于目标范围时间(Time Below Range,TBR)和低血糖事件的平均持续时间,分别在第 3、6 和 12 个月进行评估。
与第 3 个月相比,在第 6、9 和 12 个月时,GV(%)、目标范围内时间(%)、TAR 和>250mg/dL 的血糖值无显著变化(p>0.05)。然而,第 3、9 和 12 个月的平均血糖水平与基线相比有显著变化(p=0.028、p=0.048 和 p=0.022)。当将第 3 个月的平均血糖值与第 6、9 和 12 个月的平均血糖值进行比较时,没有发现显著变化(p>0.05)。与基线值相比,第 3、6、9 和 12 个月的低血糖事件(p=0.028、p=0.048、p=0.022 和 p=0.038)有显著变化。然而,除了第 12 个月(p=0.046),血糖值<70mg/dL 的比例没有显著变化。糖化血红蛋白(HbA1c)在第 3、6、9 和 12 个月与基线值相比有显著下降。
与传统的指尖采血方法相比,患者切换到 FGM 系统后,CGM 指标有显著改善,这种效果在整个研究期间都能观察到。